Cargando…

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar

Platelet activation with subsequent aggregation is a complex process leading to thrombus formation, which remains a key component for atherothrombotic manifestations, in particular myocardial infarction. Therefore, antiplatelet therapies are pivotal for the treatment of these patients. Current oral...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Jung Rae, Rollini, Fabiana, Franchi, Francesco, Ferrante, Elisabetta, Angiolillo, Dominick J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979798/ https://www.ncbi.nlm.nih.gov/pubmed/24729713 http://dx.doi.org/10.2147/VHRM.S36045

Ejemplares similares

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y(12) Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study
por: Franchi, Francesco, et al.
Publicado: (2020)

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study
por: Franchi, Francesco, et al.
Publicado: (2019)

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
por: Cavender, Matthew A., et al.
Publicado: (2015)

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction
por: Kehinde, Obamiro, et al.
Publicado: (2016)

High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar
por: Zhang, Cheng, et al.
Publicado: (2012)

Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor
por: Angiolillo, Dominick J., et al.
Publicado: (2021)

Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease
por: Gryka, Rebecca J., et al.
Publicado: (2017)

Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar
por: Farag, Mohamed, et al.
Publicado: (2015)

Unmet Needs in Managing Myocardial Infarction in Patients With Malignancy
por: Inohara, Taku, et al.
Publicado: (2019)

Mesenteric ischemia presenting as a myocardial infarction
por: Baldeo, Cherisse, et al.
Publicado: (2018)

Vorapaxar: The missing link in antiplatelet therapy!
por: Nair, Abhijit S.
Publicado: (2017)

Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation
por: Friebel, Julian, et al.
Publicado: (2021)

Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease
por: Olie, Renske H., et al.
Publicado: (2019)

Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study
por: Franchi, Francesco, et al.
Publicado: (2022)

Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations
por: Cho, Sung Won, et al.
Publicado: (2019)

Tailoring P2Y(12) Inhibiting Therapy in Elderly Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Capranzano, Piera, et al.
Publicado: (2019)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
por: Magnani, Giulia, et al.
Publicado: (2015)

Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis
por: Diehl, Philipp, et al.
Publicado: (2015)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
Publicado: (2015)

Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention
por: Sweeny, Joseph M., et al.
Publicado: (2017)

Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study
por: Franchi, Francesco, et al.
Publicado: (2021)

Unmet goals in the treatment of Acute Myocardial Infarction: Review
por: Farah, Alejandro, et al.
Publicado: (2017)

Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER
por: White, Harvey D., et al.
Publicado: (2014)

Impact of selective platelet inhibition in reducing cardiovascular risk – role of vorapaxar
por: Cheng, Judy WM
Publicado: (2016)

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention
por: Cavallari, Larisa H., et al.
Publicado: (2018)

Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice
por: Waasdorp, Maaike, et al.
Publicado: (2018)

Uncontrolled Asthma: Unmet Needs in the Management of Patients
por: Caminati, Marco, et al.
Publicado: (2021)

Wearable cardioverter-defibrillators after myocardial infarction: a review of its clinical utility and unmet needs in current clinical practice
por: Hioki, Hirofumi, et al.
Publicado: (2021)

Unmet needs in asthma
por: Gruffydd-Jones, Kevin
Publicado: (2019)

Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects
por: Kraft, WK, et al.
Publicado: (2016)

Addressing unmet needs in the treatment of COPD
por: Patalano, Francesco, et al.
Publicado: (2014)

Awareness and adherence to primary and primordial preventive measures among family members of patients with myocardial infarction-the unmet need for a “Preventive Clinic”
por: Dahiya, Neelam, et al.
Publicado: (2020)

Editorial: Challenges in Inflammatory Bowel Disease: Current, Future and Unmet Needs
por: Gravina, Antonietta Gerarda, et al.
Publicado: (2022)

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers
por: Anderson, Matt S., et al.
Publicado: (2017)

Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial
por: Ungar, Leo, et al.
Publicado: (2018)

Unmet needs in rheumatoid arthritis
por: Moreland, Larry
Publicado: (2005)

Unmet needs in the management of schizophrenia
por: Torres-González, Francisco, et al.
Publicado: (2014)

Unmet psychosocial needs in CAPS
por: Erbis, G, et al.
Publicado: (2015)

Editorial: Unmet Needs in Dystonia
por: Albanese, Alberto
Publicado: (2017)

Radiologic Gastrostomy: An Unmet Need!
por: Kumar, Mukesh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fnvoh9g8q0uueea7hireh93ln6